(Bloomberg) -- The best time to buy Pfizer Inc. and
GlaxoSmithKline Plc may be now, with their shares at a five-year
low relative to earnings and about two dozen treatments in
development designed to attack cancer.
Pfizer, the largest pharmaceutical company, is valued at
12.3 times profit, far from its peak of 72 times in 1998. Glaxo,
the second-biggest drugmaker, has a price-earnings ratio of 13.3,
the lowest in at least five years.
Read more at Bloomberg Exclusive News
GlaxoSmithKline Plc may be now, with their shares at a five-year
low relative to earnings and about two dozen treatments in
development designed to attack cancer.
Pfizer, the largest pharmaceutical company, is valued at
12.3 times profit, far from its peak of 72 times in 1998. Glaxo,
the second-biggest drugmaker, has a price-earnings ratio of 13.3,
the lowest in at least five years.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment